Close Menu

NEW YORK (GenomeWeb) — Co-Diagnostics today reported a 10 percent decline in its net loss for 2018 as the company began to generate revenues from the sale of its molecular diagnostics.

For the 12-month period ended Dec. 31, Co-Diagnostics posted a net loss of $6.3 million, or $.50 per share, versus $7.0 million, or $.63 a share, in 2017. The Salt Lake City, Utah-based firm attributed the decline to a one-time $2.1 million expense incurred in 2017 tied to the extinguishment of debt after its initial public offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

Sponsored by

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Sponsored by

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

Sponsored by

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.